EAU 2023 | ARASENS: dialuramide plus ADT and docetaxel for metastatic hormone-sensitive prostate cancer

Bertrand Tombal, MD, PhD, Université catholique de Louvain, Ottignies-Louvain-la-Neuve, Belgium, provides an overview of the Phase III ARASENS (NCT02799602) trial designed to assess dialuramide plus androgen-deprivation therapy (ADT) and docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The addition of dialuramide was shown to significantly improve all endpoints, including the primary endpoint of overall-survival (OS). Since 2015, there have been questions raised over whether patients benefited depending on the disease volume or risk. Thus, efficacy and safety were examined from the ARASENS trial for subgroups by disease volume and risk, demonstrating the addition of dialuramide benefits patients regardless of disease volume or risk. This interview took place at the EAU congress in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.